Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease01:24

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and pathologic response of neoadjuvant pulsed electric field ablation and systemic therapy in early-stage resectable lung cancer: case series.

Journal of thoracic disease·2026
Same author

Moving to better COPD care-changes to and challenges for GOLD.

American journal of respiratory and critical care medicine·2026
Same author

Mepolizumab Efficacy in COPD: Insights from Longitudinal Patterns of Blood Eosinophil Counts and Their Variability Across Three Clinical Trials.

American journal of respiratory and critical care medicine·2026
Same author

Stiffness-dependent alveolar type II cell senescence in idiopathic pulmonary fibrosis.

Cell communication and signaling : CCS·2026
Same author

Prevalence of the phenotype of lung hyperinflation and minimal emphysema in COPD.

American journal of respiratory and critical care medicine·2026
Same author

Hair follicle gene expression profiling in the SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS).

BMC medical genomics·2025

Related Experiment Videos

Tiotropium bromide for chronic obstructive pulmonary disease.

A James Mamary1, Gerard J Criner

  • 1Temple Lung Center, 745 Parkinson Pavilion, 3401 North Broad Street, Philadelphia, PA 19140, USA. albert.mamary@tuhs.temple.edu.

Expert Review of Respiratory Medicine
|May 19, 2010
PubMed
Summary

Tiotropium bromide, an inhaled anticholinergic, offers sustained bronchodilation for chronic obstructive pulmonary disease (COPD) patients. It improves lung function and quality of life while being safe and well-tolerated.

Related Experiment Videos

Area of Science:

  • Pharmacology and Clinical Medicine

Background:

  • Tiotropium bromide is a long-acting inhaled anticholinergic for chronic obstructive pulmonary disease (COPD).
  • It selectively targets M1 and M3 muscarinic receptors in the lungs, providing sustained bronchodilation.

Purpose of the Study:

  • To review the pharmacology, physiology, and safety of tiotropium in COPD management.
  • To discuss clinical studies demonstrating tiotropium's efficacy and explore its potential future therapeutic roles.

Main Methods:

  • Review of existing pharmacological data, clinical trial results, and physiological studies on tiotropium.
  • Analysis of muscarinic receptor physiology and cholinergic pathobiology in COPD and asthma.

Main Results:

  • Tiotropium improves lung function, quality of life, exercise tolerance, and reduces dyspnea and exacerbations in moderate to severe COPD.
  • Recent large trials alleviate concerns regarding cardiovascular side effects and stroke risk, confirming its safety profile.

Conclusions:

  • Tiotropium is a safe and effective treatment for COPD, offering significant clinical benefits.
  • Understanding airway muscarinic receptor physiology provides context for tiotropium's established and potential future therapeutic applications.